Healthcare
Winston Pharmaceuticals, Inc.(WPHM)
Live Price
Offline$0.0001
+0.00% today
1Y Change
-66.67%
Window
Jun 23, 2025 → Jun 12, 2026
- Market Cap
- —
- Revenue Growth
- +208.2%
- EPS Growth
- +60.0%
- Dividend Yield
- 0.0%
Coverage: 246 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Winston Pharmaceuticals, Inc. (WPHM) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 66.7% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +208.2%, EPS growth of +60.0%, a dividend yield of 0.0%. What stands out right now is revenue +208.2%, EPS +60.0%, free cash flow -36.4% with operating margin -196.6% and ROIC -561.1%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines WPHM price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+208.2% vs +7.6% peer median
Operating Margin
Below sector median
-196.6% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating story is still moving forward
Revenue is running at +208.2% and EPS at +60.0%, with operating margin around -196.6%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
WPHM
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
WPHM Max Drawdown
-66.67%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for WPHM and SPY.
Company Overview
Winston Pharmaceuticals, Inc.
Other OTC
Winston Pharmaceuticals, Inc., a pharmaceutical company, discovers, develops, and commercializes therapeutics for pain management. It focuses on pain indications, such as episodic cluster headache, chronic migraine headache, neuropathic pain syndromes, osteo-and rheumatoid arthritis, and pain and inflammation in inflammatory bowel disease, as well as niche indications. Winston Pharmaceuticals, Inc. was formerly known as Winston Laboratories, Inc. and changed its name to Winston Pharmaceuticals, Inc. in November 2008. The company was incorporated in 1998 and is headquartered in Vernon Hills, Illinois.
- Leadership
- Joel E. Bernstein
- IPO Date
- Jun 5, 2023
- Employees
- 9
- Street Address
- 100 North Fairway Drive
- Mailing
- Vernon Hills
- Region
- Vernon Hills, US
- Reporting Currency
- USD
- Investor Line
- +1 847 362 8200
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- 0.6
- Price/Sales
- 0.0
- Price/Book
- 0.0
Growth
- Revenue
- +208.2%
- EPS
- +60.0%
- Free Cash Flow
- -36.4%
Profitability
- Gross Margin
- 99.4%
- Operating Margin
- -196.6%
- Net Margin
- -190.4%
- ROE
- -156.0%
- ROIC
- -561.1%
Balance Sheet
- Debt/Equity
- —
- Current Ratio
- 1.39
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.